Is Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!

James Scopa Biography and Net Worth

Director of Adverum Biotechnologies

James Scopa, J.D., M.B.A. joined Adverum’s board in May 2019. He brings over 30 years of experience in the life sciences industry, investing in companies and advising public and private boards on strategic and financial transactions. He most recently was a managing director and member of the investment committee of MPM Capital, a global life sciences venture capital firm. Prior to MPM, Mr. Scopa spent 18 years advising growth companies in biopharmaceuticals and medical devices principally at Deutsche Banc Alex Brown and Thomas Weisel Partners. Mr. Scopa currently serves on the board of directors of Blade Therapeutics as chair of its audit committee and on its compensation committee, as well as the advisory board and the investment advisory committee of One Ventures. Mr. Scopa received an A.B. from Harvard College, an M.B.A. from Harvard Business School, and a J.D. from Harvard Law School.

What is James Paul Scopa's net worth?: The estimated net worth of James Paul Scopa is at least $47,400.00 as of February 7th, 2024. Mr. Scopa owns 10,000 shares of Adverum Biotechnologies stock worth more than $47,400 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Scopa may own. Learn More about James Paul Scopa's net worth.
How do I contact James Paul Scopa?: The corporate mailing address for Mr. Scopa and other Adverum Biotechnologies executives is 800 Saginaw Drive, Redwood City CA, 94063. Adverum Biotechnologies can also be reached via phone at (650) 656-9323 and via email at [email protected]. Learn More on James Paul Scopa's contact information.
Has James Paul Scopa been buying or selling shares of Adverum Biotechnologies?: James Paul Scopa has not been actively trading shares of Adverum Biotechnologies during the past quarter. Most recently, on Wednesday, February 7th, James Paul Scopa bought 10,000 shares of Adverum Biotechnologies stock. The stock was acquired at an average cost of $13.50 per share, with a total value of $135,000.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company's stock, valued at $135,000. Learn More on James Paul Scopa's trading history.
Who are Adverum Biotechnologies' active insiders?: Adverum Biotechnologies' insider roster includes Julie Clark (Insider), Laurent Fischer (CEO), James Scopa (Director), and Kishor Soparkar (Insider). Learn More on Adverum Biotechnologies' active insiders.
Are insiders buying or selling shares of Adverum Biotechnologies?: During the last year, Adverum Biotechnologies insiders bought shares 3 times. They purchased a total of 231,346 shares worth more than $1,798,951.50. The most recent insider tranaction occured on July, 30th when Major Shareholder Braden Michael Leonard bought 85,800 shares worth more than $613,470.00. Insiders at Adverum Biotechnologies own 4.2% of the company. Learn More about insider trades at Adverum Biotechnologies.
Information on this page was last updated on 7/30/2024.

James Paul Scopa Insider Trading History at Adverum Biotechnologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/7/2024	Buy	10,000	$13.50	$135,000.00	10,000
11/15/2021	Sell	5,000	$21.80	$109,000.00
2/14/2020	Buy	1,000	$157.90	$157,900.00
5/6/2019	Buy	2,000	$67.10	$134,200.00

James Paul Scopa Buying and Selling Activity at Adverum Biotechnologies

Adverum Biotechnologies Company Overview

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Today's Range

Now: $4.74

$4.61

$4.89

50 Day Range

MA: $6.85

$4.70

$8.48

2 Week Range

Now: $4.74

$4.61

$29.70

Volume

276,084 shs

Average Volume

277,268 shs

Market Capitalization

$98.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91

First JFK… next Elon?

From Porter & Company | Ad

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.